MCID: UTR024
MIFTS: 60

Uterine Carcinosarcoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Uterine Carcinosarcoma

MalaCards integrated aliases for Uterine Carcinosarcoma:

Name: Uterine Carcinosarcoma 12 52 58 54 6 15 17 71
Carcinosarcoma of the Corpus Uteri 52 58
Malignant Mixed Müllerian Tumor of the Corpus Uteri 52
Malignant Mixed Mullerian Tumor of the Corpus Uteri 58
Malignant Mixed Müllerian Tumor of Corpus Uteri 52
Mixed Müllerian Cancer of Corpus Uteri 52
Mixed Mullerian Cancer of Corpus Uteri 58
Mixed Mullerian Sarcoma of Uterus 12
Uterine Corpus Carcinosarcoma 71

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:6171
NCIt 49 C42700
ICD10 via Orphanet 33 C54.9
Orphanet 58 ORPHA213610
UMLS 71 C0280630 C1704376

Summaries for Uterine Carcinosarcoma

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 213610 Definition Carcinosarcoma of the corpus uteri is a rare, malignant, mixed epithelial and mesenchymal tumor of the uterine body composed of high-grade carcinomatous and sarcomatous elements. It may present with vaginal bleeding, abnormal vaginal discharge, abdominal pain and/or pelvic mass, with a polypoid tumor sometimes protruding through the cervical canal. Association with Tamoxifen therapy, long-term unopposed estrogen use and previous pelvic radiotherapy has been reported. Visit the Orphanet disease page for more resources.

MalaCards based summary : Uterine Carcinosarcoma, also known as carcinosarcoma of the corpus uteri, is related to carcinosarcoma and rhabdomyosarcoma, and has symptoms including pelvic pain An important gene associated with Uterine Carcinosarcoma is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Paclitaxel and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include uterus, lymph node and breast, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A uterine body mixed cancer that has material basis in both endometrial carcinoma and sarcoma.

Related Diseases for Uterine Carcinosarcoma

Diseases related to Uterine Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 375, show less)
# Related Disease Score Top Affiliating Genes
1 carcinosarcoma 32.3 U2AF1 TP53 PTEN PPP2R1A POLE PIK3CA
2 rhabdomyosarcoma 31.6 TP53 PTEN KIT HRAS EGFR
3 sarcoma 31.5 TP53 PTGS2 PIK3CA KIT HRAS CTNNB1
4 endometrial stromal sarcoma 31.5 U2AF1 TP53 PGR KIT
5 endometrial cancer 31.5 TP53 PTEN PPP2R1A POLE PIK3R1 PIK3CA
6 adenosarcoma 31.4 TP53 PGR KIT ERBB2
7 endometrial adenocarcinoma 31.4 TP53 PTEN PGR FGFR2 ERBB2 EGFR
8 uterine corpus serous adenocarcinoma 31.2 TP53 PTEN PPP2R1A POLE PIK3CA FBXW7
9 adenocarcinoma 31.1 TP53 PTGS2 PTEN POLE PIK3CA KIT
10 lynch syndrome 31.1 TP53 PTEN POLE PIK3CA HRAS EGFR
11 ovarian carcinosarcoma 31.1 TP53 PPP2R1A PIK3CA ERBB2
12 neuroendocrine carcinoma 31.1 PTEN KIT CDH1
13 fallopian tube carcinoma 31.1 TP53 PTEN PGR ERBB2
14 clear cell adenocarcinoma 31.1 TP53 PIK3CA PGR
15 large cell neuroendocrine carcinoma 31.0 PGR KIT ERBB2 EGFR
16 cervical squamous cell carcinoma 31.0 TP53 PIK3CA EGFR CTNNB1 CDH1
17 chordoma 30.9 TP53 PTEN EGFR CTNNB1 CDH1
18 cervical cancer 30.9 TP53 PTGS2 PTEN PIK3CA HRAS ERBB2
19 serous cystadenocarcinoma 30.9 TP53 PTEN PPP2R1A PIK3CA PGR HRAS
20 myelodysplastic syndrome 30.9 U2AF1 TP53 PTEN KIT HRAS ERBB2
21 myoma 30.7 PGR KIT EGFR
22 wilms tumor 1 30.7 U2AF1 TP53 PGR KIT HRAS FBXW7
23 colorectal cancer 30.6 U2AF1 TP53 SNAI2 PTGS2 PTEN POLE
24 squamous cell carcinoma 30.6 U2AF1 TP53 PTGS2 PTEN PIK3CA HRAS
25 breast cancer 30.3 TP53 SNAI2 PTGS2 PTEN PIK3R1 PIK3CA
26 clear cell adenofibroma 10.9 PPP2R1A PIK3CA
27 rare head and neck tumor 10.8 TP53 PIK3CA FGFR2
28 thyroid hurthle cell adenoma 10.8 PTEN PIK3CA
29 parameningeal embryonal rhabdomyosarcoma 10.8 TP53 PIK3CA FBXW7
30 ovarian clear cell adenofibroma 10.8 PTEN PIK3CA CTNNB1
31 adult hepatocellular carcinoma 10.8 TP53 PIK3CA CTNNB1
32 thyroid gland anaplastic carcinoma 10.8 TP53 PTEN PIK3CA
33 breast squamous cell carcinoma 10.8 TP53 PIK3CA HRAS ERBB2
34 vulva squamous cell carcinoma 10.8 TP53 PPP2R1A PIK3CA
35 comedo carcinoma 10.8 TP53 PGR ERBB2
36 anal squamous cell carcinoma 10.8 TP53 PIK3CA FBXW7
37 adult teratoma 10.8 TP53 HRAS FGFR2
38 glassy cell carcinoma of the cervix 10.8 PGR ERBB2
39 cervical mucinous adenocarcinoma 10.8 TP53 PTEN PGR
40 wolffian duct adenocarcinoma 10.8 TP53 HRAS FGFR2
41 epithelial-myoepithelial carcinoma 10.8 TP53 HRAS FBXW7
42 intraductal breast neoplasm 10.8 TP53 PGR ERBB2
43 breast sarcoma 10.8 TP53 PIK3CA PGR ERBB2
44 bartholin's gland adenoma 10.8 TP53 PGR
45 bartholin's gland benign neoplasm 10.8 TP53 PGR
46 vestibular gland benign neoplasm 10.8 TP53 PGR
47 embryonal sarcoma 10.8 TP53 KIT CTNNB1
48 nodular malignant melanoma 10.8 TP53 KIT HRAS
49 breast scirrhous carcinoma 10.8 PGR ERBB2 EGFR
50 mucinous lung adenocarcinoma 10.8 HRAS ERBB3 EGFR
51 mixed glioma 10.8 TP53 PTEN EGFR
52 conventional fibrosarcoma 10.8 TP53 KIT CTNNB1
53 ovarian clear cell carcinoma 10.8 TP53 PTEN PPP2R1A PIK3CA
54 vulvar intraepithelial neoplasia 10.8 TP53 CTNNB1 CDH1
55 mature teratoma 10.8 TP53 KIT ERBB2
56 breast metaplastic carcinoma 10.8 PGR ERBB2 EGFR
57 liver benign neoplasm 10.8 TP53 HRAS CTNNB1
58 apocrine adenosis of breast 10.8 TP53 PGR FGFR2 ERBB2
59 cribriform carcinoma 10.8 PGR KIT ERBB2
60 scirrhous adenocarcinoma 10.8 PGR ERBB2 CDH1
61 peritoneum cancer 10.8 TP53 ERBB2 EGFR
62 liver adenomatosis 10.8 PGR CTNNB1
63 progesterone-receptor negative breast cancer 10.8 PGR ERBB2 EGFR
64 endocervical carcinoma 10.8 U2AF1 TP53 PGR
65 gastric papillary adenocarcinoma 10.8 TP53 ERBB2
66 plexiform neurofibroma 10.8 TP53 KIT HRAS
67 gallbladder adenocarcinoma 10.8 TP53 PIK3CA ERBB2 EGFR
68 bone squamous cell carcinoma 10.8 TP53 EGFR CTNNB1
69 periampullary adenocarcinoma 10.8 ERBB3 ERBB2 EGFR
70 gliomatosis cerebri 10.8 TP53 PTEN EGFR
71 esophagus verrucous carcinoma 10.8 TP53 EGFR CDH1
72 sweat gland cancer 10.8 TP53 PGR ERBB2
73 verrucous carcinoma 10.8 TP53 PTEN ERBB3 EGFR
74 paronychia 10.8 HRAS ERBB3 ERBB2 EGFR
75 hypertrophy of breast 10.8 TP53 PTEN PIK3CA PGR ERBB2
76 neurofibromatosis, type iv, of riccardi 10.8 TP53 PTEN KIT HRAS
77 thyroid gland follicular carcinoma 10.8 TP53 PTEN HRAS
78 ovarian clear cell adenocarcinoma 10.8 TP53 PIK3CA PGR
79 primary peritoneal carcinoma 10.8 TP53 PGR ERBB2 EGFR
80 fibrillary astrocytoma 10.8 TP53 PTEN EGFR
81 gastroesophageal adenocarcinoma 10.8 PTEN ERBB2 EGFR
82 adrenocortical carcinoma, hereditary 10.8 TP53 PIK3CA CTNNB1
83 lung adenoma 10.8 TP53 PTEN HRAS EGFR
84 nevus, epidermal 10.8 PTEN PIK3CA HRAS FGFR2
85 testicular germ cell tumor 10.8 TP53 PTEN KIT HRAS
86 cystic teratoma 10.8 TP53 PTEN KIT
87 connective tissue benign neoplasm 10.8 TP53 KIT CTNNB1
88 brain stem glioma 10.8 TP53 PTEN PIK3CA EGFR
89 cystic nephroma 10.8 U2AF1 PGR KIT
90 lipid-rich carcinoma 10.8 PGR ERBB2 CDH1
91 linitis plastica 10.8 PGR ERBB2 CDH1
92 acute t cell leukemia 10.8 U2AF1 TP53 PTEN FBXW7
93 thymus gland disease 10.8 TP53 PTEN KIT EGFR
94 endocervical adenocarcinoma 10.8 U2AF1 TP53 PGR
95 breast juvenile papillomatosis 10.8 PGR ERBB2
96 thymus cancer 10.8 TP53 PTEN KIT EGFR
97 epstein-barr virus-associated gastric carcinoma 10.8 PIK3CA CTNNB1 CDH1
98 pleomorphic adenoma 10.8 TP53 HRAS ERBB2 CTNNB1
99 breast duct papilloma 10.8 PTEN PGR
100 sarcomatoid renal cell carcinoma 10.8 TP53 PTEN KIT CDH1
101 nervous system benign neoplasm 10.8 TP53 PTEN KIT
102 thyroid tumor 10.8 TP53 PTEN PIK3CA HRAS FGFR2
103 central nervous system benign neoplasm 10.8 TP53 PTEN CTNNB1
104 barrett's adenocarcinoma 10.8 TP53 PTGS2 ERBB2
105 gastric diffuse adenocarcinoma 10.8 TP53 PGR ERBB2 CDH1
106 salivary gland disease 10.8 TP53 KIT ERBB2 EGFR
107 vulva cancer 10.8 TP53 PTEN PIK3CA ERBB2 EGFR
108 neurofibroma 10.8 TP53 PTEN KIT EGFR
109 breast neuroendocrine neoplasm 10.8 PGR ERBB2 CDH1
110 signet ring cell adenocarcinoma 10.8 TP53 HRAS ERBB2 CDH1
111 liposarcoma 10.8 TP53 PTEN PIK3CA CTNNB1
112 pleomorphic carcinoma 10.8 TP53 PGR KIT EGFR
113 endometrial hyperplasia 10.8 TP53 PTEN PGR CTNNB1
114 monoclonal gammopathy of uncertain significance 10.8 U2AF1 TP53 HRAS
115 retinitis pigmentosa 11 10.8 TP53 PTEN HRAS EGFR
116 microinvasive gastric cancer 10.8 TP53 ERBB2 CDH1
117 glioma 10.8 TP53 PTEN PIK3CA ERBB2 EGFR
118 small cell carcinoma 10.8 TP53 PTEN KIT EGFR
119 exanthem 10.8 KIT HRAS ERBB2 EGFR
120 anus cancer 10.8 TP53 PIK3CA KIT HRAS EGFR
121 keratosis 10.8 TP53 PIK3CA HRAS EGFR
122 peutz-jeghers syndrome 10.8 TP53 PTEN EGFR CTNNB1
123 penile cancer 10.8 TP53 PTEN PIK3CA HRAS EGFR
124 familial colorectal cancer 10.8 TP53 POLE CDH1
125 uterine benign neoplasm 10.8 TP53 PTEN PGR HRAS CTNNB1
126 reproductive organ benign neoplasm 10.8 TP53 PTEN PGR HRAS CTNNB1
127 thyroid gland disease 10.8 U2AF1 TP53 PTEN HRAS
128 hypopharynx cancer 10.8 TP53 EGFR CDH1
129 contractures, pterygia, and variable skeletal fusions syndrome 1a 10.7 U2AF1 TP53 PTEN HRAS
130 infratentorial cancer 10.7 TP53 PTEN EGFR CTNNB1
131 breast cystic hypersecretory carcinoma 10.7 ERBB2 CDH1
132 peritoneal mesothelioma 10.7 PTEN PGR EGFR
133 papillary adenocarcinoma 10.7 TP53 PGR ERBB2 CDH1
134 pseudomyxoma peritonei 10.7 TP53 CTNNB1 CDH1
135 breast malignant phyllodes tumor 10.7 TP53 PGR KIT ERBB2 EGFR
136 bone marrow cancer 10.7 U2AF1 TP53 KIT HRAS
137 dermoid cyst 10.7 TP53 PGR KIT
138 skin papilloma 10.7 TP53 PTGS2 PTEN HRAS EGFR
139 pleuropulmonary blastoma 10.7 U2AF1 TP53 FGFR2
140 childhood medulloblastoma 10.7 TP53 ERBB3 ERBB2 EGFR CTNNB1
141 sporadic breast cancer 10.7 TP53 PTEN PGR ERBB2 EGFR
142 pancreatic ductal carcinoma 10.7 TP53 ERBB2 EGFR CDH1
143 lipid-rich breast carcinoma 10.7 PGR ERBB2
144 large cell carcinoma 10.7 KIT HRAS ERBB2 EGFR
145 rare breast tumor 10.7 TP53 PTEN PIK3CA HRAS ERBB2
146 oncocytic breast carcinoma 10.7 PGR ERBB2
147 salivary gland carcinoma 10.7 TP53 KIT ERBB2 EGFR
148 recurrent respiratory papillomatosis 10.7 ERBB2 EGFR
149 cervical adenocarcinoma 10.7 TP53 PTGS2 PTEN ERBB2 EGFR
150 thymic carcinoma 10.7 TP53 KIT EGFR
151 bilateral breast cancer 10.7 PTEN PIK3CA PGR ERBB2 CDH1
152 giant cell glioblastoma 10.7 TP53 PTEN POLE PIK3R1 EGFR
153 chronic leukemia 10.7 U2AF1 PTEN KIT
154 mucinous adenocarcinoma 10.7 TP53 PGR KIT ERBB2 EGFR
155 inflammatory breast carcinoma 10.7 PGR ERBB2 EGFR CDH1
156 mammary paget's disease 10.7 PGR ERBB2 EGFR
157 breast fibroadenoma 10.7 TP53 PGR ERBB2
158 ovarian serous carcinoma 10.7 TP53 ERBB2 CDH1
159 autosomal genetic disease 10.7 U2AF1 TP53 PTEN HRAS
160 ovarian seromucinous carcinoma 10.7 TP53 PGR
161 rectum adenocarcinoma 10.7 TP53 POLE PIK3CA HRAS ERBB2 EGFR
162 small intestine cancer 10.7 TP53 HRAS ERBB2 CTNNB1 CDH1
163 respiratory system benign neoplasm 10.7 TP53 PTEN HRAS EGFR CDH1
164 central nervous system cancer 10.7 U2AF1 TP53 PTEN EGFR
165 lobular neoplasia 10.7 TP53 PGR ERBB2 CTNNB1 CDH1
166 nervous system cancer 10.7 U2AF1 TP53 PTEN EGFR
167 desmoid tumor 10.7 PTGS2 KIT CTNNB1
168 thymoma 10.7 TP53 PIK3CA KIT HRAS EGFR
169 amelogenesis imperfecta, type ig 10.7 PGR ERBB2 EGFR
170 esophageal basaloid squamous cell carcinoma 10.7 TP53 EGFR
171 cervical serous adenocarcinoma 10.7 PGR CTNNB1
172 vagina leiomyosarcoma 10.7 PGR KIT
173 leukemia 10.7 U2AF1 TP53 KIT HRAS ERBB3 ERBB2
174 microglandular adenosis 10.7 TP53 PGR ERBB2 EGFR CDH1
175 breast papillary carcinoma 10.7 PGR ERBB2
176 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 1 10.7 TP53 POLE PIK3R1
177 oral submucous fibrosis 10.7 TP53 PTGS2 CDH1
178 estrogen-receptor negative breast cancer 10.7 PGR ERBB2 EGFR
179 laryngeal squamous cell carcinoma 10.7 TP53 PTEN EGFR CDH1
180 germinoma 10.7 U2AF1 KIT CDH1
181 oral cancer 10.7 TP53 PTGS2 EGFR CDH1
182 actinic keratosis 10.7 TP53 PTGS2 HRAS
183 mucoepidermoid carcinoma 10.7 TP53 ERBB2 EGFR CDH1
184 skeletal muscle cancer 10.7 TP53 KIT HRAS
185 glioma susceptibility 1 10.7 TP53 PTEN PIK3CA HRAS ERBB2 EGFR
186 rare adenocarcinoma of the breast 10.7 TP53 PIK3CA
187 thoracic benign neoplasm 10.7 TP53 PGR ERBB2 EGFR CDH1
188 breast benign neoplasm 10.7 TP53 PGR ERBB2 EGFR CDH1
189 muscle cancer 10.7 TP53 KIT HRAS
190 papilloma 10.7 TP53 PTGS2 PTEN EGFR CDH1
191 dysgerminoma 10.7 PTEN KIT FGFR2
192 spindle cell carcinoma 10.7 SNAI2 PGR HRAS CDH1
193 malignant anus melanoma 10.7 KIT HRAS
194 obsolete: squamous cell carcinoma of head and neck 10.7 TP53 PTEN PIK3CA HRAS EGFR CTNNB1
195 female breast cancer 10.7 TP53 PGR ERBB2
196 adenosquamous carcinoma 10.7 TP53 PTEN PIK3CA PGR KIT EGFR
197 juvenile myelomonocytic leukemia 10.7 U2AF1 TP53 PTEN HRAS
198 spitz nevus 10.7 TP53 HRAS
199 cystadenocarcinoma 10.7 TP53 PPP2R1A PIK3CA PGR HRAS FBXW7
200 cystadenoma 10.7 PTEN PGR KIT
201 small cell cancer of the lung 10.7 U2AF1 TP53 PTEN PIK3CA KIT EGFR
202 teratoma 10.7 TP53 PTEN KIT CTNNB1 CDH1
203 esophagus adenocarcinoma 10.7 TP53 PTGS2 ERBB2 EGFR CDH1
204 endometrioid ovary carcinoma 10.7 TP53 PTEN PPP2R1A POLE PIK3CA HRAS
205 autonomic nervous system neoplasm 10.7 U2AF1 TP53 PTEN HRAS ERBB2 EGFR
206 immunodeficiency 14 10.7 PTEN PIK3R1
207 adenoma 10.7 TP53 PTGS2 PIK3CA CTNNB1 CDH1
208 differentiated thyroid carcinoma 10.7 TP53 HRAS EGFR
209 gallbladder disease 10.7 TP53 HRAS ERBB2 EGFR CDH1
210 hemangioma 10.7 TP53 PTEN PGR KIT
211 li-fraumeni syndrome 10.7 TP53 PTEN HRAS ERBB2 EGFR CTNNB1
212 cystitis 10.7 TP53 PTGS2 KIT CDH1
213 keratoacanthoma 10.7 TP53 EGFR CDH1
214 esophageal disease 10.7 TP53 ERBB2 EGFR CDH1
215 tongue cancer 10.7 TP53 PTEN EGFR CTNNB1 CDH1
216 skin melanoma 10.7 U2AF1 TP53 PTGS2 KIT HRAS ERBB2
217 lung benign neoplasm 10.7 TP53 HRAS EGFR
218 thyroid carcinoma 10.7 TP53 PTEN PIK3CA HRAS CTNNB1 CDH1
219 sarcomatoid transitional cell carcinoma 10.7 TP53 CDH1
220 colorectal adenoma 10.7 TP53 PTGS2 HRAS CTNNB1 CDH1
221 breast adenocarcinoma 10.7 TP53 PIK3CA PGR ERBB3 ERBB2 EGFR
222 tubular adenocarcinoma 10.7 PGR ERBB2 EGFR CTNNB1 CDH1
223 familial adenomatous polyposis 10.7 TP53 PTGS2 HRAS CTNNB1 CDH1
224 uterine anomalies 10.7 U2AF1 TP53 PTEN PGR
225 uterine corpus endometrial carcinoma 10.7 U2AF1 TP53 PTEN PPP2R1A POLE PIK3R1
226 melanoma, uveal 10.7 U2AF1 TP53 PTEN KIT HRAS EGFR
227 pancreas disease 10.7 U2AF1 TP53 HRAS EGFR
228 bile duct adenocarcinoma 10.7 TP53 PTEN HRAS ERBB2 EGFR CDH1
229 ovarian cystadenocarcinoma 10.7 TP53 PTEN PIK3CA HRAS ERBB2 EGFR
230 oral cavity cancer 10.7 TP53 PTEN PIK3CA ERBB2 EGFR CDH1
231 colonic disease 10.7 U2AF1 TP53 HRAS EGFR
232 gliosarcoma 10.7 TP53 SNAI2 PTEN PIK3R1 ERBB2 EGFR
233 skin squamous cell carcinoma 10.7 TP53 PTEN KIT HRAS EGFR CDH1
234 breast carcinoma in situ 10.7 TP53 PTEN PGR ERBB2 EGFR CDH1
235 vulvar disease 10.7 TP53 PIK3CA PGR KIT HRAS ERBB2
236 oligodendroglioma 10.7 TP53 PTGS2 PTEN EGFR
237 cholecystitis 10.7 TP53 EGFR CDH1
238 extracutaneous mastocytoma 10.7 U2AF1 KIT
239 adenomyosis 10.7 TP53 PTGS2 PTEN PGR CTNNB1 CDH1
240 bent bone dysplasia syndrome 10.7 FGFR2 ERBB2
241 peripheral nervous system neoplasm 10.7 U2AF1 TP53 PTEN KIT HRAS ERBB2
242 melanoma, cutaneous malignant 1 10.7 TP53 PTEN PIK3CA KIT HRAS EGFR
243 estrogen-receptor positive breast cancer 10.7 TP53 PIK3CA PGR FGFR2 ERBB3 ERBB2
244 mantle cell lymphoma 10.7 TP53 PTEN PIK3CA KIT
245 thymoma, familial 10.7 KIT HRAS
246 acneiform dermatitis 10.7 HRAS EGFR
247 colonic benign neoplasm 10.7 TP53 PTGS2 HRAS EGFR CTNNB1 CDH1
248 skin carcinoma 10.7 TP53 PTGS2 HRAS EGFR CDH1
249 clear cell renal cell carcinoma 10.7 TP53 PTEN EGFR CTNNB1 CDH1
250 tongue disease 10.7 TP53 SNAI2 PTEN EGFR CTNNB1 CDH1
251 peptic ulcer disease 10.7 TP53 PTGS2 HRAS
252 brain cancer 10.7 TP53 PTEN PIK3CA HRAS EGFR CTNNB1
253 gastrointestinal system benign neoplasm 10.7 TP53 PTGS2 HRAS EGFR CTNNB1 CDH1
254 goblet cell carcinoid 10.7 CTNNB1 CDH1
255 urinary tract obstruction 10.7 PTGS2 PIK3CA CDH1
256 ureteral obstruction 10.7 TP53 PTGS2 CTNNB1
257 rare cancer of corpus uteri 10.7 TP53 PTEN PPP2R1A PIK3CA HRAS FGFR2
258 barrett esophagus 10.7 TP53 PTGS2 ERBB2 EGFR CTNNB1 CDH1
259 tongue squamous cell carcinoma 10.7 TP53 SNAI2 PTEN EGFR CTNNB1 CDH1
260 myeloproliferative neoplasm 10.7 U2AF1 KIT HRAS EGFR
261 esophagitis 10.7 TP53 PTGS2 EGFR
262 leukemia, chronic myeloid 10.7 U2AF1 TP53 PTEN KIT HRAS ERBB2
263 in situ carcinoma 10.7 TP53 PTEN PGR HRAS ERBB2 EGFR
264 intratubular embryonal carcinoma 10.6 TP53 KIT
265 cowden syndrome 10.6 TP53 PTEN POLE PIK3R1 PIK3CA HRAS
266 bile duct cancer 10.6 TP53 PTEN HRAS ERBB2 EGFR CTNNB1
267 pancreatic ductal adenocarcinoma 10.6 TP53 PTEN HRAS ERBB2 EGFR CTNNB1
268 eccrine papillary adenoma 10.6 PIK3CA HRAS
269 intrahepatic cholangiocarcinoma 10.6 TP53 PTEN FGFR2 ERBB2 EGFR CTNNB1
270 muscular disease 10.6 U2AF1 TP53 PTEN PGR KIT HRAS
271 breast ductal carcinoma 10.6 TP53 PTEN PGR ERBB2 EGFR CTNNB1
272 leukemia, chronic lymphocytic 10.6 U2AF1 TP53 PTEN KIT HRAS ERBB2
273 meningioma, familial 10.6 TP53 PTEN PGR KIT ERBB2 EGFR
274 gastrointestinal stromal tumor 10.6 TP53 PTGS2 PTEN KIT ERBB2 EGFR
275 tonsil cancer 10.6 TP53 SNAI2 PGR KIT ERBB2 EGFR
276 hair disease 10.6 TP53 ERBB2 EGFR
277 frontal lobe neoplasm 10.6 TP53 EGFR
278 transitional cell carcinoma 10.6 TP53 PTGS2 PTEN HRAS ERBB3 ERBB2
279 intestinal benign neoplasm 10.6 TP53 PTGS2 PTEN PIK3CA HRAS EGFR
280 leopard syndrome 10.6 PIK3R1 PIK3CA HRAS
281 gallbladder cancer 10.6 TP53 PTGS2 PTEN PIK3CA ERBB2 EGFR
282 colon adenocarcinoma 10.6 TP53 PTGS2 PTEN PIK3CA ERBB2 EGFR
283 thoracic cancer 10.6 U2AF1 TP53 PGR ERBB2
284 laryngeal disease 10.6 TP53 EGFR CDH1
285 oropharynx cancer 10.6 TP53 PTEN PIK3CA PGR KIT HRAS
286 malignant ovarian surface epithelial-stromal neoplasm 10.6 TP53 PTEN PIK3CA PGR HRAS ERBB2
287 parotid gland cancer 10.6 TP53 ERBB2
288 myelofibrosis 10.6 U2AF1 TP53 KIT HRAS
289 lymphatic system disease 10.6 U2AF1 TP53 KIT
290 ductal carcinoma in situ 10.6 TP53 PTGS2 PTEN PIK3CA PGR ERBB3
291 ovarian disease 10.6 TP53 PTEN PIK3CA PGR KIT HRAS
292 pre-malignant neoplasm 10.6 TP53 PTGS2 PTEN PIK3CA PGR HRAS
293 female reproductive endometrioid cancer 10.6 TP53 PTEN PPP2R1A POLE PIK3R1 PIK3CA
294 luminal breast carcinoma 10.6 TP53 SNAI2 PTEN PIK3CA PGR ERBB3
295 retinitis pigmentosa 10.6 U2AF1 TP53 PTEN KIT HRAS ERBB2
296 liver leiomyoma 10.6 PGR KIT
297 colorectal adenocarcinoma 10.6 TP53 PTGS2 PTEN KIT HRAS ERBB2
298 basal cell carcinoma 10.6 TP53 SNAI2 PTGS2 PTEN KIT EGFR
299 myeloma, multiple 10.6 U2AF1 TP53 PTEN KIT HRAS ERBB2
300 cholangiocarcinoma 10.6 TP53 PTGS2 PTEN PIK3CA FGFR2 ERBB2
301 renal cell carcinoma, nonpapillary 10.6 TP53 PTEN PIK3CA KIT HRAS FGFR2
302 lung squamous cell carcinoma 10.6 TP53 SNAI2 PTEN PIK3CA HRAS FGFR2
303 ovary adenocarcinoma 10.5 TP53 PTEN PPP2R1A PIK3CA PGR HRAS
304 retroperitoneal leiomyosarcoma 10.5 KIT ERBB3
305 renal cell carcinoma, papillary, 1 10.5 U2AF1 TP53 PTEN PIK3CA KIT HRAS
306 ovary epithelial cancer 10.5 U2AF1 TP53 PTEN PIK3CA PGR HRAS
307 bladder urothelial carcinoma 10.5 U2AF1 TP53 PTEN PIK3CA KIT HRAS
308 leukemia, acute myeloid 10.5 U2AF1 TP53 PTEN KIT HRAS FBXW7
309 bladder cancer 10.5 TP53 PTGS2 PTEN PIK3CA HRAS FGFR2
310 breast disease 10.5 TP53 PPP2R1A PGR ERBB2
311 melanoma 10.5 TP53 PTEN PIK3R1 PIK3CA KIT HRAS
312 malignant dermis tumor 10.5 KIT HRAS
313 cell type benign neoplasm 10.5 TP53 PTGS2 PTEN PIK3CA PGR KIT
314 nasopharyngeal carcinoma 10.5 TP53 SNAI2 PTGS2 PTEN PIK3CA HRAS
315 neuroblastoma 10.5 TP53 PTGS2 PTEN PIK3CA KIT HRAS
316 ovarian serous cystadenocarcinoma 10.5 TP53 PTEN PPP2R1A PIK3CA PGR HRAS
317 mixed cell type cancer 10.5 TP53 PTEN PPP2R1A PIK3CA PGR KIT
318 breast adenoid cystic carcinoma 10.5 PGR ERBB2
319 thyroid gland cancer 10.5 U2AF1 TP53 PTEN PIK3CA KIT HRAS
320 breast mucinous carcinoma 10.5 PGR ERBB2
321 medulloblastoma 10.5 TP53 PTGS2 PTEN PIK3CA KIT HRAS
322 adenoid cystic carcinoma 10.4 TP53 SNAI2 PTEN PIK3CA PGR KIT
323 uterine corpus cancer 10.4 U2AF1 TP53 PTEN PPP2R1A POLE PIK3R1
324 glioblastoma multiforme 10.4 TP53 PTGS2 PTEN PIK3R1 PIK3CA KIT
325 uterine body mixed cancer 10.4 U2AF1 TP53 SNAI2 PTEN PPP2R1A POLE
326 squamous cell carcinoma, head and neck 10.4 U2AF1 TP53 SNAI2 PTGS2 PTEN PIK3CA
327 suppression of tumorigenicity 12 10.4 U2AF1 TP53 SNAI2 PTGS2 PTEN PIK3CA
328 uterine sarcoma 10.4
329 gastric adenocarcinoma 10.4 TP53 PTGS2 PTEN PIK3CA KIT HRAS
330 pancreatic adenocarcinoma 10.4 U2AF1 TP53 PTGS2 PTEN POLE PIK3CA
331 malignant skin fibrous histiocytoma 10.4 KIT HRAS
332 esophageal cancer 10.4 TP53 SNAI2 PTGS2 PTEN PIK3CA HRAS
333 lung cancer susceptibility 3 10.4 U2AF1 TP53 SNAI2 PTGS2 PTEN PIK3CA
334 hepatocellular carcinoma 10.4 TP53 SNAI2 PTGS2 PTEN PIK3R1 PIK3CA
335 leiomyosarcoma 10.4
336 pancreatic cancer 10.4 TP53 SNAI2 PTGS2 PTEN PIK3R1 PIK3CA
337 squamous cell papilloma 10.3 TP53 HRAS
338 gastric cancer 10.3 TP53 PTGS2 PTEN PIK3R1 PIK3CA PGR
339 prostate cancer 10.3 TP53 SNAI2 PTGS2 PTEN PIK3R1 PIK3CA
340 spindle cell sarcoma 10.3
341 rare tumor 10.3
342 ovarian cancer 10.3 TP53 SNAI2 PTGS2 PTEN PIK3R1 PIK3CA
343 lung cancer 10.2 U2AF1 TP53 SNAI2 PTGS2 PTEN PIK3R1
344 sensory peripheral neuropathy 10.2
345 overgrowth syndrome 10.2
346 cowden syndrome 1 10.1 PTEN PIK3CA EGFR
347 suppressor of tumorigenicity 3 10.1
348 endometriosis 10.1
349 chondrosarcoma 10.1
350 neutropenia 10.1
351 thrombocytosis 10.1
352 mesenchymal cell neoplasm 10.1
353 chromosomal triplication 10.1
354 retinoblastoma 9.9
355 sarcoidosis 1 9.9
356 rhabdomyosarcoma, embryonal, 1 9.9
357 wilms tumor 5 9.9
358 angiosarcoma 9.9
359 hepatoid adenocarcinoma 9.9
360 hemopericardium 9.9
361 cardiac tamponade 9.9
362 pericardial effusion 9.9
363 constipation 9.9
364 anuria 9.9
365 embryonal rhabdomyosarcoma 9.9
366 vaginal discharge 9.9
367 cervical carcinosarcoma 9.9
368 familial retinoblastoma 9.9
369 peripheral nervous system disease 9.9
370 neuropathy 9.9
371 adenosarcoma of the uterus 9.9
372 triploidy 9.9
373 didelphys uterus 9.9
374 carcinosarcoma of the cervix uteri 9.9
375 rare gynecological tumor 9.9

Graphical network of the top 20 diseases related to Uterine Carcinosarcoma:



Diseases related to Uterine Carcinosarcoma

Symptoms & Phenotypes for Uterine Carcinosarcoma

UMLS symptoms related to Uterine Carcinosarcoma:


pelvic pain

GenomeRNAi Phenotypes related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

26 (showing 48, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.63 EGFR HRAS PIK3CA
2 Decreased viability GR00106-A-0 10.63 ERBB3
3 Decreased viability GR00221-A-1 10.63 CDH1 KIT EGFR HRAS PIK3CA PIK3R1
4 Decreased viability GR00221-A-2 10.63 ERBB3 HRAS PIK3CA
5 Decreased viability GR00221-A-3 10.63 HRAS PIK3R1
6 Decreased viability GR00221-A-4 10.63 ERBB3 EGFR PIK3CA
7 Decreased viability GR00301-A 10.63 CDH1 ERBB3 FGFR2 KIT
8 Decreased viability GR00342-S-1 10.63 FGFR2
9 Decreased viability GR00342-S-2 10.63 ERBB3 FGFR2
10 Decreased viability GR00342-S-3 10.63 ERBB3 FGFR2
11 Decreased viability GR00402-S-2 10.63 CDH1 ERBB3 FGFR2 KIT EGFR HRAS
12 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.23 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.23 EGFR
14 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.23 ERBB3
15 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.23 U2AF1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.23 EGFR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.23 POLE
18 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.23 U2AF1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.23 KIT
20 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.23 KIT
21 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.23 ERBB3
22 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.23 ERBB2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.23 ERBB2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.23 ERBB2 POLE
25 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.23 KIT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.23 EGFR
27 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.23 ERBB3
28 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.23 POLE
29 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.23 EGFR
30 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.23 U2AF1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.23 EGFR
32 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.23 KIT
33 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.23 ERBB2 POLE
34 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.23 KIT
35 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.23 EGFR
36 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.23 ERBB2 ERBB3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.23 ERBB2 POLE
38 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.23 EGFR ERBB2 ERBB3 KIT POLE U2AF1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.23 KIT
40 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.23 KIT
41 Decreased substrate adherent cell growth GR00193-A-1 9.97 ERBB3 KIT
42 Decreased substrate adherent cell growth GR00193-A-2 9.97 EGFR ERBB3 FGFR2 KIT
43 Decreased substrate adherent cell growth GR00193-A-3 9.97 FGFR2
44 Decreased substrate adherent cell growth GR00193-A-4 9.97 KIT
45 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.95 CTNNB1 EGFR ERBB2 FGFR2 HRAS PPP2R1A
46 Increased cell death HMECs cells GR00103-A-0 9.91 CTNNB1 EGFR ERBB3 FBXW7 PGR PIK3CA
47 Increased cell viability after pRB stimulation GR00230-A-1 9.46 EGFR ERBB2 ERBB3 KIT
48 Reduced mammosphere formation GR00396-S 9.28 CDH1 EGFR ERBB3 HRAS PIK3R1 POLE

MGI Mouse Phenotypes related to Uterine Carcinosarcoma:

45 (showing 27, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.53 CDH1 CTNNB1 EGFR ERBB2 ERBB3 FBXW7
2 homeostasis/metabolism MP:0005376 10.5 CDH1 CTNNB1 EGFR ERBB2 ERBB3 FBXW7
3 endocrine/exocrine gland MP:0005379 10.49 CDH1 CTNNB1 EGFR ERBB2 ERBB3 FBXW7
4 growth/size/body region MP:0005378 10.49 CDH1 CTNNB1 EGFR ERBB2 ERBB3 FBXW7
5 mortality/aging MP:0010768 10.49 CDH1 CTNNB1 EGFR ERBB2 ERBB3 FBXW7
6 integument MP:0010771 10.48 CDH1 CTNNB1 EGFR ERBB2 ERBB3 FBXW7
7 embryo MP:0005380 10.47 CDH1 CTNNB1 EGFR ERBB2 ERBB3 FBXW7
8 cellular MP:0005384 10.46 CDH1 CTNNB1 EGFR ERBB2 ERBB3 FBXW7
9 immune system MP:0005387 10.46 CDH1 CTNNB1 EGFR ERBB3 FBXW7 FGFR2
10 behavior/neurological MP:0005386 10.44 CTNNB1 ERBB2 ERBB3 FGFR2 HRAS KIT
11 digestive/alimentary MP:0005381 10.42 CDH1 CTNNB1 EGFR ERBB2 ERBB3 FBXW7
12 neoplasm MP:0002006 10.41 CDH1 CTNNB1 EGFR ERBB2 ERBB3 FBXW7
13 hematopoietic system MP:0005397 10.39 CTNNB1 EGFR FBXW7 FGFR2 KIT PGR
14 normal MP:0002873 10.28 CDH1 CTNNB1 EGFR ERBB2 ERBB3 FBXW7
15 muscle MP:0005369 10.27 CTNNB1 EGFR ERBB2 ERBB3 FGFR2 KIT
16 nervous system MP:0003631 10.27 CTNNB1 EGFR ERBB2 ERBB3 FBXW7 FGFR2
17 craniofacial MP:0005382 10.26 CTNNB1 EGFR ERBB2 FBXW7 FGFR2 HRAS
18 adipose tissue MP:0005375 10.18 EGFR FGFR2 PIK3CA PIK3R1 PTEN PTGS2
19 liver/biliary system MP:0005370 10.18 CTNNB1 EGFR FBXW7 FGFR2 KIT PIK3R1
20 limbs/digits/tail MP:0005371 10.14 CTNNB1 EGFR ERBB2 FGFR2 KIT PGR
21 no phenotypic analysis MP:0003012 10.13 CDH1 CTNNB1 EGFR FGFR2 HRAS KIT
22 reproductive system MP:0005389 10.03 CDH1 CTNNB1 EGFR ERBB2 FGFR2 KIT
23 pigmentation MP:0001186 9.97 CTNNB1 EGFR ERBB3 FGFR2 KIT PTEN
24 renal/urinary system MP:0005367 9.92 CTNNB1 EGFR FGFR2 HRAS KIT PTEN
25 respiratory system MP:0005388 9.9 CTNNB1 EGFR ERBB2 ERBB3 FBXW7 FGFR2
26 skeleton MP:0005390 9.73 CTNNB1 EGFR ERBB2 FGFR2 HRAS KIT
27 vision/eye MP:0005391 9.32 CTNNB1 EGFR FBXW7 FGFR2 KIT PIK3CA

Drugs & Therapeutics for Uterine Carcinosarcoma

Drugs for Uterine Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 46, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
2
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
3
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
4
Mesna Approved, Investigational Phase 3 3375-50-6 598
5
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
6
Ifosfamide Approved Phase 3 3778-73-2 3690
7
Lenograstim Approved, Investigational Phase 3 135968-09-1
8
Histamine Approved, Investigational Phase 3 51-45-6 774
9
Cyproheptadine Approved Phase 3 129-03-3 2913
10 Antimitotic Agents Phase 3
11 Albumin-Bound Paclitaxel Phase 3
12 Alkylating Agents Phase 3
13 Anti-Bacterial Agents Phase 3
14 Antibiotics, Antitubercular Phase 3
15 Topoisomerase Inhibitors Phase 3
16
Liposomal doxorubicin Phase 3 31703
17
Isophosphamide mustard Phase 3 0
18 Gastrointestinal Agents Phase 3
19 Neurotransmitter Agents Phase 3
20 Dermatologic Agents Phase 3
21 Histamine Antagonists Phase 3
22 Serotonin Agents Phase 3
23 Histamine H1 Antagonists Phase 3
24 Serotonin Antagonists Phase 3
25 Anti-Allergic Agents Phase 3
26
Histamine Phosphate Phase 3 51-74-1 65513
27 Antipruritics Phase 3
28
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
29
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
30
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
31
Gemcitabine Approved Phase 2 95058-81-4 60750
32
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
33
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
34
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
35
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
36
Iniparib Investigational Phase 2 160003-66-7
37 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
38 Immunologic Factors Phase 2
39 Angiogenesis Inhibitors Phase 2
40 Anti-Infective Agents Phase 2
41 Immunosuppressive Agents Phase 2
42 Antimetabolites Phase 2
43 Antiviral Agents Phase 2
44 Protein Kinase Inhibitors Phase 2
45 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
46 topoisomerase I inhibitors Phase 2

Interventional clinical trials:

(showing 20, show less)
# Name Status NCT ID Phase Drugs
1 A Phase III Randomized Study of Accelerated Hyperfractionated Whole Abdominal Radiotherapy (AHWAR) Versus Combination Ifosfamide-Mesna With Cisplatin in Optimally Debulked Stage I, II, III, or IV Carcinosarcoma (CS) of The Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
2 Phase III Randomized Study of Adjuvant Pelvic Radiotherapy Versus Observation Alone in Patients With Completely Resected, Stage I or II, High-Grade Uterine Sarcoma Completed NCT00002459 Phase 3
3 A Phase III Trial of Ifosfamide (NSC #109274) Versus Ifosfamide Plus Paclitaxel (NSC #125973) in Patients With Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
4 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
5 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
6 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
7 A Phase II Evaluation of Paclitaxel (Taxol, NSC # 673089) and Carboplatin (Paraplatin, NSC #241240) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00112489 Phase 2 carboplatin;paclitaxel
8 A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
9 Phase II Study of Thalidomide (NSC #66847) in Patients With Sarcomas of Gynecologic Origin Completed NCT00006005 Phase 2 thalidomide
10 Evaluation of Doxil in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
11 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
12 A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
13 Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
14 A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
15 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
16 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
17 Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Not yet recruiting NCT02993705 Phase 2 Trabectedin
18 Evaluation of Topotecan in the Treatment of Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus Terminated NCT00003156 Phase 2 topotecan hydrochloride
19 A Pilot Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With Uterine Carcinosarcoma Unknown status NCT01367301 paclitaxel;carboplatin
20 A Prospective Study of the Impact of Surgical and Pathologic Tissue Sampling Methods on Lymph Node Counts and Detection of Lymph Node Metastasis in Endometrial Cancer Staging Completed NCT02335775

Search NIH Clinical Center for Uterine Carcinosarcoma

Genetic Tests for Uterine Carcinosarcoma

Anatomical Context for Uterine Carcinosarcoma

MalaCards organs/tissues related to Uterine Carcinosarcoma:

40
Uterus, Lymph Node, Breast, Lung, Endothelial, Brain, Colon

Publications for Uterine Carcinosarcoma

Articles related to Uterine Carcinosarcoma:

(showing 369, show less)
# Title Authors PMID Year
1
Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. 54 61
20189232 2010
2
COX-2 expression in uterine carcinosarcoma. 61 54
19900134 2010
3
Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. 54 61
17175012 2007
4
Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment? 54 61
16445668 2006
5
HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy. 54 61
15901136 2005
6
Cyclooxygenase-2 expression in uterine leiomyosarcomas. 54 61
15700850 2004
7
ERBB-2 gene overexpression and amplification in uterine sarcomas. 54 61
15581967 2004
8
Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. 54 61
14611676 2003
9
Uterine carcinosarcoma is derived from a single stem cell: an in vitro study. 54 61
9311600 1997
10
Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms. 61
31789001 2020
11
Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition. 61
31772025 2019
12
Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies. 61
31833974 2019
13
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. 61
31765263 2019
14
Prognostic significance of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in uterine carcinosarcoma. 61
31739121 2019
15
Does chemotherapy or radiation benefit surgical stage I uterine carcinosarcoma patients? 61
31765639 2019
16
Neutrophilia and mortality in women with uterine carcinosarcoma. 61
31320488 2019
17
Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA. 61
31607216 2019
18
Unique Molecular Features in High-Risk Histology Endometrial Cancers. 61
31717878 2019
19
[Ifosfamide and Paclitaxel for Recurrent or Metastatic Uterine Carcinosarcoma]. 61
31631133 2019
20
Uterine Carcinosarcomas. 61
31375170 2019
21
Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A. 61
31416848 2019
22
Uterine carcinosarcoma: a primer for radiologists. 61
31030248 2019
23
Uterine Inversion as a Result of a Large Prolapsed Carcinosarcoma of the Uterus. 61
30686610 2019
24
Effect of Adjuvant Therapy on Oncologic Outcomes of Surgically Confirmed Stage I Uterine Carcinosarcoma: a Turkish Gynecologic Oncology Study 61
30873825 2019
25
Outcome of adjuvant radiotherapy after total hysterectomy in patients with uterine leiomyosarcoma or carcinosarcoma: a SEER-based study. 61
31307426 2019
26
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. 61
30229512 2019
27
Cytological features of uterine carcinosarcoma: A retrospective study of 20 cases with an emphasis on the usefulness of endometrial cytology. 61
30706679 2019
28
Brain Metastasis in a Young Patient with Uterine Carcinosarcoma. 61
31497440 2019
29
Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years. 61
31196490 2019
30
Predictive Histologic Factors in Carcinosarcomas of the Uterus: A Multi-institutional Study. 61
30958427 2019
31
Cancer antigen 125 is associated with disease status in uterine carcinosarcoma. 61
31741727 2019
32
Immunohistochemical analysis of the epithelial to mesenchymal transition in uterine carcinosarcoma. 61
30636710 2019
33
Molecular classification and subtype-specific drug sensitivity research of uterine carcinosarcoma under multi-omics framework. 61
30359167 2019
34
Current Status of Magnetic Resonance Imaging in Patients with Malignant Uterine Neoplasms: A Review. 61
30627019 2019
35
Prognostic factors impacting survival in early stage uterine carcinosarcoma. 61
30414738 2019
36
Ultrasonographic Findings of Uterine Carcinosarcoma. 61
30504724 2019
37
[A Case of Laparoscopic Surgery Performed for Lynch Syndrome in a Patient Who Developed Cecal Cancer and Uterine Carcinosarcoma Synchronously]. 61
30692278 2018
38
Radiation-Induced Uterine Carcinosarcoma after Concurrent Chemoradiotherapy for Cervical Squamous Cell Carcinoma. 61
30308682 2018
39
Diagnostic Value of 18F-FDG PET/CT and MRI in the Preoperative Evaluation of Uterine Carcinosarcoma. 61
30538776 2018
40
Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma. 61
30105438 2018
41
L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition. 61
30140948 2018
42
Clinical utility of CA-125 in the management of uterine carcinosarcoma. 61
30207096 2018
43
Uterine carcinosarcoma (malignant mixed Müllerian tumor): case report in a goat and literature review. 61
30345891 2018
44
Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas. 61
30194005 2018
45
The Adrenal Gland as a Sanctuary Site of Metastases After Pembrolizumab Treatment: A Case Series. 61
30442730 2018
46
Patterns of Adjuvant Therapy Utilization in Uterine Carcinosarcoma Stages I to III: A National Cancer Database Analysis. 61
28654573 2018
47
Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. 61
30026381 2018
48
A case of uterine carcinosarcoma which was strongly suspected to have metastases to the psoas and gluteus muscles. 61
31149529 2018
49
Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma. 61
29971677 2018
50
Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element. 61
30217299 2018
51
Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma: Patterns of Care and Impact on Overall Survival. 61
28121642 2018
52
Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE-Mutant Uterine Carcinosarcoma. 61
29386312 2018
53
A Case of Uterine Carcinosarcoma Detected Simultaneously with Breast and Colon Cancer (Triple Primary Malignant Tumor). 61
30057538 2018
54
The Association of an Elevated Thrombocyte Count with Clinicopathological Prognostic Factors and Survival in Patients with Uterine Carcinosarcoma. 61
29629727 2018
55
Fluorodeoxyglucose Positron Emission Tomography-computed Tomography Evaluation of an Interesting Case of Uterine Carcinosarcoma with Isolated Appendicular Skeletal Metastases. 61
29643680 2018
56
Predictive Histologic Factors in Carcinosarcomas of the Uterus: A Multiinstitutional Study. 61
29620586 2018
57
Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. 61
29455465 2018
58
Female Sex Hormone Receptor Profiling in Uterine Adenosarcomas. 61
29303935 2018
59
Trends of uterine carcinosarcoma in the United States. 61
29400015 2018
60
Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. 61
29044542 2018
61
Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma. 61
28836024 2018
62
Significance of venous thromboembolism in women with uterine carcinosarcoma. 61
29248197 2018
63
[I. Clinical Development and Prospect of Chemotherapy for Uterine Carcinosarcoma]. 61
29483412 2018
64
Prognostic Significance of omental Disease and the Role of Omental Sampling in Patients With Uterine Carcinosarcoma. 61
29303931 2018
65
Diagnostic accuracy of 3.0T diffusion-weighted MRI for patients with uterine carcinosarcoma: Assessment of tumor extent and lymphatic metastasis. 61
29437265 2018
66
Impact of radiotherapy modalities on outcomes in the adjuvant management of uterine carcinosarcoma: A National Cancer Database analysis. 61
29097136 2018
67
Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study. 61
29791913 2018
68
Uterine Carcinosarcomas - Diagnosis and Management. 61
30317231 2018
69
Genomic profiling identifies GPC5 amplification in association with sarcomatous transformation in a subset of uterine carcinosarcomas. 61
29416878 2018
70
Epigenetic silencing of lncRNA MORT in 16 TCGA cancer types. 61
29707199 2018
71
Uterine Carcinosarcoma with Alpha-Fetoprotein-Producing Hepatoid Component: A Case Report and Literature Review. 61
29992073 2018
72
Outcomes of carcinosarcoma in a tertiary care institution in India. 61
29600231 2018
73
Role of Radiation Therapy in the Multidisciplinary Management of Uterine Carcinosarcoma. 61
28930812 2018
74
Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. 61
29056442 2017
75
Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C. 61
29130934 2017
76
Fascin Is Associated With Aggressive Behavior and Poor Outcome in Uterine Carcinosarcoma. 61
28704324 2017
77
Port-Site Metastasis of Uterine Carcinosarcoma after Laparoscopy. 61
28960047 2017
78
Aberrant chromatin remodeling in gynecological cancer. 61
29113150 2017
79
A unique case of malignant mixed müllerian tumor with metastasis to the thyroid: a case report. 61
28777428 2017
80
CNS metastasis secondary to malignant-mixed Müllerian tumor: case report and review of therapeutics. 61
28990810 2017
81
Uterine Carcinosarcomas: Clinical, Histopathologic and Immunohistochemical Characteristics. 61
28700424 2017
82
Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma. 61
28657223 2017
83
Towards precision medicine: discovering novel gynecological cancer biomarkers and pathways using linked data. 61
28927463 2017
84
Secondary uterine carcinosarcoma after concurrent chemoradiotherapy for cervical cancer: Case reports. 61
28761924 2017
85
A predictive diagnostic model using multiparametric MRI for differentiating uterine carcinosarcoma from carcinoma of the uterine corpus. 61
28584958 2017
86
Prognostic value of metabolic parameters determined by preoperative ¹⁸F-FDG PET/CT in patients with uterine carcinosarcoma. 61
28541634 2017
87
Use of Adjuvant Chemotherapy, Radiation Therapy, or Combined Modality Therapy and the Impact on Survival for Uterine Carcinosarcoma Limited to the Pelvis. 61
28574930 2017
88
Expression of aurora kinases: Predictor of tumor dissemination in uterine carcinosarcoma. 61
27779297 2017
89
Primitive Neuroectodermal Tumors of the Female Genital Tract: A Morphologic, Immunohistochemical, and Molecular Study of 19 Cases. 61
28296680 2017
90
Comprehensive Staging of Uterine Carcinosarcoma Using a Multiquadrant Robotic Platform. 61
27794476 2017
91
Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives. 61
28531111 2017
92
Durable complete remission with aromatase inhibitor therapy in a patient with metastatic uterine carcinosarcoma with poor performance status and coagulation disorders: a case report. 61
28424084 2017
93
Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS. 61
27889902 2017
94
Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. 61
28215838 2017
95
Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy. 61
28317560 2017
96
Integrated Molecular Characterization of Uterine Carcinosarcoma. 61
28292439 2017
97
Synchronous uterine adenocarcinoma and leiomyosarcoma - a case study. 61
28546804 2017
98
High Incidence of Carcinosarcoma among Patients Previously Treated with Tamoxifen. 61
28457094 2017
99
Functional role of ALK-related signal cascades on modulation of epithelial-mesenchymal transition and apoptosis in uterine carcinosarcoma. 61
28193280 2017
100
Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma. 61
28088687 2017
101
Identification of distinct molecular subtypes of uterine carcinosarcoma. 61
28178664 2017
102
Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. 61
27931750 2017
103
Clinical Outcomes for Stereotactic Ablative Radiotherapy in Oligometastatic and Oligoprogressive Gynecological Malignancies. 61
27870704 2017
104
Malignant Mixed Müllerian Tumour of the Uterus: Analysis of 44 Cases. 61
28092915 2017
105
Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. 61
28630682 2017
106
A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. 61
28029447 2017
107
Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08). 61
27550404 2016
108
Prognostic value of total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with uterine carcinosarcoma. 61
26883331 2016
109
Rare case of an ovarian vein tumor thrombosis identified on fluorodeoxyglucose positron emission tomography/computed tomography. 61
27833321 2016
110
Uterine carcinosarcoma including angiosarcoma: A short case report. 61
27592347 2016
111
Prognostic impact of primary tumor SUVmax on preoperative 18F-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography in endometrial cancer and uterine carcinosarcoma. 61
27703679 2016
112
Carcinosarcoma of the uterus: MRI findings including diffusion-weighted imaging and MR spectroscopy. 61
26787673 2016
113
[Uterine Carcinosarcoma: Clinicopathological Features and Prognostic Factors]. 61
28103458 2016
114
RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma. 61
27121792 2016
115
Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas. 61
27761279 2016
116
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma. 61
27052653 2016
117
Utility of histogram analysis of apparent diffusion coefficient maps obtained using 3.0T MRI for distinguishing uterine carcinosarcoma from endometrial carcinoma. 61
26605502 2016
118
Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group. 61
27072806 2016
119
Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study. 61
27441069 2016
120
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. 61
27014780 2016
121
Unusual Cutaneous Metastasis of Uterine Carcinosarcoma: A Case Report and Review of the Literature. 61
26675357 2016
122
Adjuvant radiation therapy in uterine carcinosarcoma: A population-based analysis of patient demographic and clinical characteristics, patterns of care and outcomes. 61
26896827 2016
123
Combination of adjuvant chemotherapy and radiotherapy is associated with improved survival at early stage type II endometrial cancer and carcinosarcoma. 61
26890292 2016
124
Carcinosarcoma of the uterus: A case report. 61
27073665 2016
125
Comparison of MRI and 18F-FDG PET/CT in the preoperative evaluation of uterine carcinosarcoma. 61
26777990 2016
126
An uncommon response to metronomic therapy in a heavily pretreated patient with metastatic carcinosarcoma: a case report. 61
26971567 2016
127
Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study. 61
26463439 2016
128
Nestin: A biomarker of aggressive uterine cancers. 61
26718725 2016
129
Cooperation of Sox4 with β-catenin/p300 complex in transcriptional regulation of the Slug gene during divergent sarcomatous differentiation in uterine carcinosarcoma. 61
26841870 2016
130
Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. 61
26084780 2016
131
Clinical Characteristics, Surgical Management and Adjuvant Therapy of Patients with Uterine Carcinosarcoma: A Retrospective Case Series. 61
26941453 2016
132
Genetic Investigation of Uterine Carcinosarcoma: Case Report and Cohort Analysis. 61
27009459 2016
133
Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping. 61
25994210 2016
134
Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. 61
27172745 2016
135
The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study. 61
26509850 2016
136
Extent of lymph node dissection and overall survival in patients with uterine carcinosarcoma, papillary serous and endometrioid adenocarcinoma: A retrospective cohort study. 61
26476418 2015
137
A survey of DICER1 hotspot mutations in ovarian and testicular sex cord-stromal tumors. 61
26428316 2015
138
Delayed and clinically isolated port site carcinosarcoma recurrence as an early indicator of disseminated disease. 61
26793764 2015
139
Clinically aggressive "low-grade" uterine carcinosarcoma: A case report. 61
26793763 2015
140
Review of Recommended Treatment of Uterine Carcinosarcoma. 61
26374341 2015
141
A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma. 61
26348313 2015
142
Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: a National Cancer Database analysis. 61
26307402 2015
143
The Effect of Cyclooxygenase-2 Expression in Uterine Carcinosarcoma on Survival: A Reassessment Based on Mature Data. 61
26222488 2015
144
Uterine carcinosarcoma/malignant mixed Müllerian tumor incidence is increased in women with breast cancer, but independent of hormone therapy. 61
26404129 2015
145
Evaluation of brachytherapy and external beam radiation therapy for early stage, node-negative uterine carcinosarcoma. 61
26166579 2015
146
Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna. 61
26254376 2015
147
Advanced Chemoembolization by Anti-angiogenic Calcium-Phosphate Ceramic Microspheres Targeting the Vascular Heterogeneity of Cancer Xenografts. 61
26254366 2015
148
In-depth molecular profiling of the biphasic components of uterine carcinosarcomas. 61
27499902 2015
149
Vaginal brachytherapy for early-stage carcinosarcoma of the uterus. 61
25890795 2015
150
Role of TGF-β signaling in uterine carcinosarcoma. 61
25918253 2015
151
Uterine carcinosarcoma: A review of the literature. 61
25805398 2015
152
Evaluation of postoperative chemotherapy in patients with uterine carcinosarcoma: a retrospective survey of the Tohoku Gynecologic Cancer Unit. 61
25030547 2015
153
Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison. 61
25633654 2015
154
Azaspirene analogs inhibit the growth of human uterine carcinosarcoma in vitro and in vivo. 61
25964553 2015
155
Racial disparities in treatment of high-grade endometrial cancer in the Medicare population. 61
25751197 2015
156
Rare uterine cancer: carcinosarcomas. Review from histology to treatment. 61
25468677 2015
157
Adjuvant treatment modalities, prognostic predictors and outcomes of uterine carcinosarcomas. 61
25358384 2015
158
Survival impact of cytoreduction to microscopic disease for advanced stage cancer of the uterine corpus: a retrospective cohort study. 61
25576762 2015
159
Clinical outcomes of uterine carcinosarcoma: results of 94 patients. 61
25611900 2015
160
URI1 amplification in uterine carcinosarcoma associates with chemo-resistance and poor prognosis. 61
26328264 2015
161
Postradiation carcinosarcoma of the corpus uteri--a case report. 61
26775366 2015
162
Uterine sarcomas: clinical presentation and MRI features. 61
25347940 2015
163
Non-Islet Cell Tumor Hypoglycemia Is Caused by Big IGF-II in a Patient with a Carcinosarcoma of the Uterus. 61
26666605 2015
164
T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. 61
25398397 2015
165
Paclitaxel and carboplatin in patients with completely or optimally resected carcinosarcoma of the uterus: a phase II trial by the Japanese Uterine Sarcoma Group and the Tohoku Gynecologic Cancer Unit. 61
25347097 2015
166
Case report of uterine carcinosarcoma with incisional site recurrence. 61
25404826 2014
167
Co-existence of primary fallopian tube carcinoma and uterine carcinosarcoma. 61
24912001 2014
168
Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma. 61
25084509 2014
169
Carboplatin-Paclitaxel versus Cisplatin-Ifosfamide in the treatment of uterine carcinosarcoma: a retrospective cohort study. 61
25078338 2014
170
Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors. 61
25078343 2014
171
Carcinosarcoma of the uterine corpus on 18F-FDG PET/CT in a postmenopausal woman with elevated AFP. 61
24152629 2014
172
Pathologic prognostic factors in stage I-III uterine carcinosarcoma treated with postoperative radiotherapy. 61
24633893 2014
173
Review literature on uterine carcinosarcoma. 61
25313723 2014
174
Robotic surgery compared with laparotomy for high-grade endometrial cancer. 61
27637526 2014
175
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. 61
24594074 2014
176
Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: a population-based analysis. 61
24561247 2014
177
Black race independently predicts worse survival in uterine carcinosarcoma. 61
24613675 2014
178
Metastatic calcaneal lesion associated with uterine carcinosarcoma. 61
23871174 2014
179
Prognostic factors and status of hormone receptors and angiogenic factors in uterine carcinosarcoma. 61
24320058 2014
180
Eight cases of malignant mixed Müllerian tumor (carcinosarcoma) of the uterus: findings in SurePath™ cervical cytology. 61
22865798 2014
181
Synchronous uterine carcinosarcoma and contralateral breast cancer after tamoxifen therapy: a case report. 61
25197413 2014
182
AlloDerm graft mimicking uterine carcinosarcoma recurrence on PET/CT. 61
24359070 2014
183
Retrospective analysis of 80 cases with uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma in China, 1988-2007. 61
24817958 2014
184
Humoral hypercalcemia caused by uterine corpus carcinosarcoma consisting of squamous cell carcinoma in its epithelial component. 61
24033661 2014
185
[Integrative management using Ayurvedic medicine in a patient with advanced malignant mixed Muellerian tumor - a case report]. 61
24603630 2014
186
Treatment outcomes in completely resected stage I to stage IV uterine carcinosarcoma with rhabdomyosarcoma differentiation. 61
24172099 2013
187
TGFβ-pathway is down-regulated in a uterine carcinosarcoma: a case study. 61
23932095 2013
188
AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma. 61
23896716 2013
189
Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma. 61
23599147 2013
190
[Uterine carcinosarcoma]. 61
24227518 2013
191
Prognostic determinants in patients with uterine and ovarian carcinosarcoma. 61
23947079 2013
192
Wilms' tumor 1 protein and estrogen receptor beta expression are associated with poor outcomes in uterine carcinosarcoma. 61
23344579 2013
193
The reasonable timing of the adjuvant radiotherapy in the treatment of uterine carcinosarcoma according to the surgical intent: suggestion based on progression patterns. 61
23865003 2013
194
Is there an increase in the incidence of uterine carcinosarcoma in north-east Scotland? A 19 years population-based cohort study. 61
23728753 2013
195
Expression of steroid and xenobiotic receptor in uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma. 61
23443531 2013
196
Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. 61
23450572 2013
197
[Uterine Carcinosarcoma induced by a vaginal foreign body: a case report and review]. 61
23062745 2013
198
Impact of multimodal therapy on the survival of patients with newly diagnosed uterine carcinosarcoma. 61
24020131 2013
199
Unexpected long-term survival in a BRCA2 patient with metastatic carcinosarcoma associated with tamoxifen. 61
24371674 2013
200
Uterine carcinosarcoma in a patient with didelphys uterus. 61
23533863 2013
201
Carcinosarcoma of the corpus uteri (Malignant Müllerian Mixed Tumor): a case report in Yaoundé (Cameroon). 61
24876903 2013
202
Impact of treatment strategies on local control and survival in uterine carcinosarcomas in Turkey. 61
23803061 2013
203
A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. 61
22796461 2012
204
A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. 61
22727985 2012
205
[Adjuvant radiochemotherapy of uterine carcinosarcoma in need of optimization]. 61
22915184 2012
206
Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study. 61
22634397 2012
207
[Uterine carcinosarcoma]. 61
23342885 2012
208
[Uterine carcinosarcoma]. 61
23156287 2012
209
Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma. 61
22969950 2012
210
Prognostic value of alternative lengthening of telomeres-associated biomarkers in uterine sarcoma and uterine carcinosarcoma. 61
22266933 2012
211
Expression profiles of carcinosarcoma of the uterine corpus-are these similar to carcinoma or sarcoma? 61
22072501 2012
212
Uterine carcinosarcoma associated with pelvic radiotherapy for sacral chordoma: a case report. 61
22482976 2012
213
Prognostic impact of the history of breast cancer and of hormone therapy in uterine carcinosarcoma. 61
22228427 2012
214
Uterine carcinosarcoma with scalp metastasis; a rare presentation. 61
22214642 2012
215
DR6 as a diagnostic and predictive biomarker in adult sarcoma. 61
22567163 2012
216
Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma. 61
22055846 2012
217
Cervical adenocarcinoma presenting as a cardiac tamponade in a 57-year-old woman: a case report. 61
22188664 2011
218
Long-term recurrence-free survival in a patient with stage IVB uterine carcinosarcoma. 61
22247807 2011
219
Uterine carcinosarcoma with p53-positive intraepithelial component. 61
22026369 2011
220
The influence of adjuvant radiotherapy on patterns of failure and survivals in uterine carcinosarcoma. 61
22984675 2011
221
The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma. 61
21945551 2011
222
Stage III uterine carcinosarcoma: 2009 International Federation of Gynecology and Obstetrics Staging System and Prognostic Determinants. 61
21720252 2011
223
FIGO staging for carcinosarcoma: can the revised staging system predict overall survival? 61
21889193 2011
224
An update on the management of uterine carcinosarcoma. 61
22186602 2011
225
CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor). 61
21919130 2011
226
Uterine carcinosarcoma. 61
21743326 2011
227
Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts. 61
21631643 2011
228
Uterine carcinosarcomas: 8-year single center experience of 25 cases. 61
22557781 2011
229
Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers. 61
21161468 2011
230
Uterine carcinosarcoma. 61
21508698 2011
231
A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma. 61
21436700 2011
232
Uterine Carcinosarcoma in a 2-year-old Female Wistar Hannover GALAS Rat. 61
22272045 2011
233
Carcinosarcoma of the uterine corpus with alpha-fetoprotein-producing hepatoid adenocarcinoma: a report of two cases. 61
21769295 2011
234
Expression and localization of E-cadherin and β-catenin in uterine carcinosarcoma. 61
21046151 2011
235
[Carcinosarcoma of the corpus uteri: potential of p53, PTEN and COX-2 expression for survival]. 61
21809666 2011
236
Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. 61
21249682 2011
237
[Uterine carcinosarcoma in a patient using tamoxifen]. 61
21136375 2010
238
Co-expression of GPR30 and ERbeta and their association with disease progression in uterine carcinosarcoma. 61
20605134 2010
239
A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study. 61
20452658 2010
240
Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay. 61
19875949 2010
241
Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes. 61
20606539 2010
242
Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. 61
20421537 2010
243
A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. 61
20347480 2010
244
Carcinosarcoma arising in uterine didelphys after tamoxifen therapy for breast cancer: a case report. 61
20524448 2010
245
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. 61
20117828 2010
246
Carcinosarcoma of the uterus in a woman with Down syndrome. 61
20890074 2010
247
Polypoid or non-polypoid? A novel dichotomous approach to uterine carcinosarcoma. 61
19640575 2009
248
Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: implications for adjuvant therapy. 61
19574779 2009
249
Uterine carcinosarcoma metastatic to the lung as large-cell neuroendocrine carcinoma with synchronous sarcoid granulomatosis. 61
19111933 2009
250
Requirement of the Akt/beta-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug. 61
19389926 2009
251
[Tamoxifen in the adjuvant setting for breast cancer: Reflexions about the risk of uterine carcinosarcoma]. 61
19394886 2009
252
Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma. 61
19201517 2009
253
Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma. 61
19200930 2009
254
[Uterine carcinosarcomas associated with tamoxifen therapy. Report of two cases and review of the literature]. 61
19135318 2009
255
Pheophorbide a based photodynamic therapy induces apoptosis via mitochondrial-mediated pathway in human uterine carcinosarcoma. 61
19276676 2009
256
Inflammatory myofibroblastic tumour of the urinary bladder mimicking recurrent uterine carcinosarcoma. 61
19309402 2009
257
Malignant pericardial effusion and cardiac tamponade originating from uterine carcinosarcoma. 61
18548260 2009
258
Endometrial cancer state of the science meeting. 61
19258955 2009
259
[Investigation of biological features of uterine carcinosarcoma]. 61
20210020 2009
260
[Uterine carcinosarcoma with chondroid differentiation--immuhistochemical examination]. 61
20198774 2009
261
Carcinosarcoma of the uterus: radiologic-pathologic correlations with magnetic resonance imaging including diffusion-weighted imaging. 61
18501546 2008
262
A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. 61
18755503 2008
263
Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. 61
18674808 2008
264
Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution. 61
18602677 2008
265
The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma. 61
18160157 2008
266
[A case of uterine carcinosarcoma]. 61
18834571 2008
267
Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. 61
18591309 2008
268
[The diagnostic problem of uterine sarcomas: report on a case of carcinosarcoma mimicking a gastro-intestinal disease]. 61
18407437 2008
269
[Clinical analysis of 12 cases of uterine carcinosarcoma]. 61
18479602 2008
270
Array-based comparative genomic hybridization (aCGH) analysis is a useful tool for distinguishing primary pulmonary from metastatic neuroendocrine carcinoma to the lung. 61
18301238 2008
271
Uterine carcinosarcoma in a patient with hereditary non-polyposis coli. 61
18065215 2008
272
18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma. 61
17952435 2008
273
Characterization of a newly established uterine carcinosarcoma cell line featuring the sarcomatous phenotype of the tumor in vitro. 61
18334012 2008
274
Prognostic factors and adjuvant therapy in uterine carcinosarcoma. 61
19051818 2008
275
Immunohistochemical analysis of carcinomatous and sarcomatous components in the uterine carcinosarcoma: a case report. 61
18207653 2008
276
Carcinosarcoma of the uterus: a case report and review of the literature. 61
19051829 2008
277
Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. 61
17935762 2007
278
Prognostic features of surgical stage I uterine carcinosarcoma. 61
18059221 2007
279
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. 61
17822748 2007
280
Uterine carcinosarcoma associated with hereditary nonpolyposis colorectal cancer. 61
17666659 2007
281
Occult metastatic lung carcinoma presenting as locally advanced uterine carcinosarcoma on positron emission tomography/computed tomography imaging. 61
17504386 2007
282
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. 61
17290061 2007
283
Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4. 61
16996111 2007
284
The uterine carcinosarcoma - a case report. 61
18060197 2007
285
DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. 61
16810312 2006
286
Uterine carcinosarcoma arising from an endometrial polyp: assessment by 3-dimensional power Doppler angiography and positron emission tomography/computed tomography. 61
16632794 2006
287
Clinical features and outcomes of uterine and ovarian carcinosarcoma. 61
16271748 2006
288
Defective DNA mismatch repair and XRCC2 mutation in uterine carcinosarcomas. 61
16169065 2006
289
[Uterine carcinosarcoma in a teenager: report of a case macroscopically mimicking rhabdomyosarcoma]. 61
16457389 2005
290
Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. 61
15975641 2005
291
Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. 61
15972232 2005
292
A comparison between different postoperative treatment modalities of uterine carcinosarcoma. 61
15790453 2005
293
Differential diagnosis between uterine carcinosarcoma versus carcinoma with sarcomatous metaplasia: an immunohistochemical and ultrastructural case study. 61
16028671 2005
294
The combination of Jun N-terminal kinase inhibitor and TNP-470 blocks carcinosarcoma-induced endothelial cell tube formation in a synergistic manner. 61
15737687 2005
295
COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies? 54
15589595 2005
296
Expression of c-kit in uterine carcinosarcoma. 61
15589603 2005
297
Localization of the VEGF and angiopoietin genes in uterine carcinosarcoma. 61
15581949 2004
298
Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features. 61
15494858 2004
299
An abnormal cervicovaginal cytology smear in uterine carcinosarcoma is an adverse prognostic sign: analysis of 25 cases. 61
15362375 2004
300
Cytology of vaginal and uterine sarcomas. 61
15471250 2004
301
Histogenesis of carcinosarcoma and establishment of leiomyosarcoma cell line (HTMMT) derived from human uterine carcinosarcoma. 61
15859158 2004
302
Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. 61
15350372 2004
303
Importance of the endometrioid carcinoma subtype and sarcomatous component in uterine carcinosarcoma. 61
15047252 2004
304
Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma. 61
15086737 2004
305
Carcinosarcoma-induced endothelial cells tube formation through KDR/Flk-1 is blocked by TNP-470. 61
14670616 2004
306
2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth. 61
14599859 2003
307
[Uterine carcinosarcoma related to tamoxifen]. 61
14675359 2003
308
Expression and intracellular localization of Smad proteins in human endometrial cancer. 61
12883738 2003
309
Effect of angiogenesis inhibitor TNP-470 on the growth, blood flow, and microvessel density in xenografts of human uterine carcinosarcoma in nude mice. 61
12694659 2003
310
Cure of metastatic uterine carcinosarcoma to lungs: a case report. 61
12631227 2003
311
Uterine carcinosarcoma with complete sarcomatous overgrowth mimicking pure embryonal rhabdomyosarcoma. 61
12496704 2003
312
Expression of TGF-beta type I and II receptors in normal and cancerous human endometrium. 61
12213293 2002
313
Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. 61
12445244 2002
314
Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. 61
12366669 2002
315
Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? 61
11986333 2002
316
Unsuspected uterine carcinosarcoma (heterologous) diagnosed following conservative therapies with medroxyprogesterone acetate for presumed early-stage endometrial carcinoma. 61
12069197 2002
317
Cyclooxygenase-2 expression in malignant mesenchymal tumors and related uterine lesions. 54
11605037 2001
318
Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival. 61
11585418 2001
319
CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. 61
11532038 2001
320
Uterine carcinosarcoma with melanocytic differentiation. 61
11293166 2001
321
Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population. 61
11373106 2001
322
K-ras exon 2 point mutations in human endometrial cancer. 61
11179836 2001
323
Markers of apoptosis and angiogenesis indicate that carcinomatous components play an important role in the malignant behavior of uterine carcinosarcoma. 61
11150369 2000
324
Differential expression of matrix metalloprotease-7 in each component of uterine carcinosarcoma. 61
11032915 2000
325
Combined diagnostic imaging of uterine carcinosarcoma: A case report. 61
11240709 2000
326
Diagnosis of recurrent uterine carcinosarcoma by fine-needle aspiration cytology: report of a case. 61
10888756 2000
327
Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases. 61
11240687 2000
328
Long-term tamoxifen treatment: a possible aetiological factor in the development of uterine carcinosarcoma: two case-reports and review of the literature. 61
10928144 2000
329
p53 protein detection by the western blotting technique in normal and neoplastic specimens of human endometrium. 61
10695997 2000
330
TNP-470 inhibits growth and the production of vascular endothelial growth factor of uterine carcinosarcoma cells in vitro. 61
10769702 2000
331
Angiogenesis in carcinosarcomas of the uterus: differences in the microvessel density and expression of vascular endothelial growth factor between the epithelial and mesenchymal elements. 61
10534173 1999
332
Trousseau's syndrome with brachiocephalic vein thrombosis in a patient with uterine carcinosarcoma. A case report. 61
10378829 1999
333
Neovascularization of uterine carcinosarcoma: report of two cases analyzed by color Doppler ultrasonography and microvessel density. 61
10206221 1999
334
Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients. 61
9452269 1998
335
The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. 61
9454652 1998
336
Expression of ras p21 in the stromal cells of human neoplastic endometrium. 61
9641239 1998
337
An evaluation of prognostic factors in uterine carcinosarcoma. 61
9441781 1997
338
Uterine carcinosarcoma in association with tamoxifen therapy. 61
9422027 1997
339
Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. 61
9345359 1997
340
Characteristics of rhabdomyosarcoma cell lines derived from uterine carcinosarcomas. 61
9368662 1997
341
Uterine carcinosarcoma in association with tamoxifen therapy. 61
9197885 1997
342
The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. 61
9190981 1997
343
Retinoblastoma protein expression in endometrial hyperplasia and carcinoma. 61
9159330 1997
344
Characterization of platelet aggregation induced by the human carcinosarcoma Colo 526: role of platelet activation, tumor cell cytoskeleton and tumor cell plasma membrane. 61
9213340 1997
345
The hormonal receptor status of uterine carcinosarcomas (mixed müllerian tumours): an immunohistochemical study. 61
9215151 1997
346
[Carcinosarcoma of the corpus uteri--a case report]. 61
10756758 1997
347
Carcinosarcoma of the uterus with extensive neuroectodermal differentiation. 61
8971564 1996
348
Simultaneous expression of the ras p21 and p53 proteins in human endometrial carcinomas. 61
8960305 1996
349
[Sequential course and prospective management of ifosfamide-induced multi-organ toxicity]. 61
9036065 1996
350
Tissue polypeptide antigen production in a uterine carcinosarcoma cell line in a serum-free culture. 61
8774655 1996
351
[A case of remission of recurrent carcinosarcoma of the uterus with massive ascites by carboplatin]. 61
7661577 1995
352
Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Müllerian tumor) of the uterus? 61
11578496 1995
353
Carcinosarcoma (malignant mixed müllerian tumor) of the uterus with a rhabdoid tumor component. An immunohistochemical, ultrastructural, and immunoelectron microscopic case study. 61
7856569 1995
354
[Uterine mixed malignant mesodermal tumors--a case with an unusual distribution of components]. 61
8313481 1993
355
Establishment and characterization of carcinosarcoma cell line of the human uterus. 61
8431860 1993
356
Characterization and estrogen regulation of growth factor activity from uterus. 61
2753231 1989
357
Uterine carcinosarcoma. Case report. 61
2627972 1989
358
Plasma-dependent and -independent mechanisms of platelet aggregation induced by human tumour cell lines. 61
3629545 1987
359
[A case report of uterine carcinosarcoma with alpha-fetoprotein (AFP) production]. 61
2435929 1987
360
Extra-uterine müllerian carcinosarcoma. 61
3811858 1986
361
Carcinosarcoma of the uterus: a 40-year experience from the state of Missouri. 61
6714806 1984
362
Histogenesis and culture of human uterine carcinosarcoma. 61
7194144 1981
363
Uterine sarcoma following adjuvant radiotherapy for rectal carcinoma. 61
7230832 1981
364
Regression of metastatic uterine carcinosarcoma. Following cyclophosphamide chemotherapy. 61
4510802 1973
365
[CARCINOSARCOMA OF THE CORPUS UTERI DEVELOPING 6 YEARS AFTER RADIOTHERAPY OF CANCER OF THE CERVIX UTERI]. 61
14251876 1964
366
[A case of carcinosarcoma of the corpus uteri with tumor infiltration of simultaneous endometriosis interna]. 61
13756727 1960
367
[Case of uterine carcinosarcoma]. 61
14950021 1952
368
[Histopathology of uterine carcinosarcoma]. 61
14932426 1952
369
[Uterine carcinosarcoma]. 61
14853378 1951